A research team at the Seoul National University Bundang Hospital (SNUBH) has released the results of phase 1 clinical trial of a new treatment that kills cancer cells of pancreatic cancer patients. In the trial, the researchers tested a method that used “genetically modified adenovirus,” in which two different cancer treatment genes are inserted, on patients with irresectable pancreatic cancer.
Pancreatic cancer is deadly cancer that people fear most because of its poor prognosis, as shown by a five-year survival rate of only about 12.2 percent. Read more . . .